HPV-DNA testing for cervical cancer precursors: From evidence to clinical practice

ecancermedicalscience

Volumn 6, Issue 1, 2012, Pages

  Origoni, Massimo ^a   Cristoforoni, P ^b   Costa, S ^c   Mariani, L ^d   Scirpa, P ^e   Lorincz, A ^f   Sideri, M ^g  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^g EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Cervical cancer; HPV DNA; Human papillomavirus (HPV); Screening

Indexed keywords

CARCINOMA IN SITU; CLINICAL PRACTICE; COLPOSCOPY; COST BENEFIT ANALYSIS; DNA SCREENING; EVIDENCE BASED PRACTICE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TESTING; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; NONHUMAN; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PREDICTIVE VALUE; REVIEW; SENSITIVITY ANALYSIS; STUDY DESIGN; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VACCINATION;

EID: 84863588846     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2012.258     Document Type: Review

References (65)

1. Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ and Solomon D (2007). 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests Am J Obstet Gynecol 163 346-55 DOI: 10.1016/j.ajog.2007.07.047 (Pubitemid 47464164)
2. Gross PA, Barrett TL, Dellinger EP et al (1994) Purpose of quality standards for infectious diseases. Infectious Diseases Society of America Clin Infect Dis 18 421 DOI: 10.1093/clinids/18.3.421 PMID: 8011826 (Pubitemid 24086315)
3. Kish MA (2001) Guide to development of practice guidelines Clin Infect Dis 32 851-4 DOI: 10.1086/319366 PMID: 11247707 (Pubitemid 32524817)
4. Cuzick J, Clavel C, Petry KU et al (2006) Overview of the European and North American studies on HPV testing in primary cervical cancer screening Int J Cancer 119 1095-101 DOI: 10.1002/ijc.21955 PMID: 16586444 (Pubitemid 44116919)
5. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Kolipoulos G, Dillner J (2006) Chapter 9. Clinical applications of HPV testing: a summary of meta-analyses Vaccine 24 (suppl) 78-89 DOI: 10.1016/j.vaccine.2006.05.117
6. Petry KU, Menton S, Menton M et al (2003) Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients Br J Cancer 88 1570-7 DOI: 10.1038/sj.bjc.6600918 PMID: 12771924 (Pubitemid 36713784)
7. Sherman ME, Lorincz AT, Scott DR et al (2003) Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis J Natl Cancer Inst 95 46-52 DOI: 10.1093/jnci/95.1.46 PMID: 12509400 (Pubitemid 36124295)
8. Hoyer H, Scheungraber C, Kuehne-Heid R et al (2005) Cumulative 5-year diagnoses of CIN2, CIN3 or cervical cancer after concurrent high-risk HPV and cytology testing in a primary screening setting Int J Cancer 116 136-43 DOI: 10.1002/ijc.20955 PMID: 15756677 (Pubitemid 40827767)
9. Bulkmans NW, Berkhof J, Rozendaal L et al (2007) Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial Lancet 370 1764-72 DOI: 10.1016/S0140-6736(07)61450-0 PMID: 17919718 (Pubitemid 350137476)
10. Kitchener HC, Almonte M, Wheeler P et al (2006) HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial Br J Cancer 95 56-61 DOI: 10.1038/sj.bjc.6603210 PMID: 16773068 (Pubitemid 43980554)
11. Kotaniemi-Talonen L, Nieminen P, Anttila A, Hakama M (2005) Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting Br J Cancer 93 862-7 DOI: 10.1038/sj.bjc.6602799 PMID: 16189520 (Pubitemid 41487010)
12. Naucler P, Ryd W, Tornberg S et al (2007) Human papillomavirus and papanicolaou tests to screen for cervical cancer N Engl J Med 357 1589-97 DOI: 10.1056/NEJMoa073204 PMID: 17942872 (Pubitemid 47598401)
13. Sankaranarayanan R, Nene BM, Shastri SS et al (2009) HPV screening for cervical cancer in rural India N Engl J Med 360 1385-94 DOI: 10.1056/NEJMoa0808516 PMID: 19339719
14. Ronco G, Giorgi-Rossi P, Carozzi F et al for the New Technologies for Cervical Cancer screening (NTCC) Working Group. (2010) Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial Lancet Oncol 11 249-57 DOI: 10.1016/S1470-2045(09)70360-2 PMID: 20089449
15. Dillner J, Rebolj M, Birembaut P et al (2008) Long term predictive values of cytology and Human Papillomavirus testing in cervical cancer screening: joint European cohort study BMJ 377 a1754 DOI: 10.1136/bmj.a1754
16. Carozzi F, Del Mistro A, Confortini M et al (2005) Reproducibility of HPV-DNA testing by hybrid capture 2 in a screening setting Am J Clin Pathol 124 716-21 DOI: 10.1309/84E5WHJQHK83BGQD PMID: 16203283
17. Naucler P, Ryd W, Törnberg S et al (2009) Efficacy of HPV-DNA testing with cytology triage and/or repeat HPV-DNA testing in primary cervical cancer screening J Natl Cancer Inst 101 88-99 DOI: 10.1093/jnci/djn444 PMID: 19141778
18. Khan MJ, Castle PE, Lorincz AT et al (2005) The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice J Natl Cancer Inst 97 1072-9 DOI: 10.1093/jnci/dji187 PMID: 16030305 (Pubitemid 41417924)
19. Carozzi F, Confortini M, Dalla Palma P et al (2008) Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial Lancet Oncol 9 937-45 DOI: 10.1016/S1470-2045(08)70208-0 PMID: 18783988
20. Wright TC Jr, Schiffman M, Solomon D et al (2004) Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening Obstet Gynecol 103 304-9 DOI: 10.1097/01.AOG.0000109426.82624.f8
21. National Cancer Institute Workshop (1989) The 1988 Bethesda system for reporting cervical/vaginal cytological diagnoses. JAMA 262 931-4 PMID: 2754794
22. Kurman RJ, Solomon D, Nayar R, Davey D, Wilbur D (2003) The Bethesda System for Reporting Cervical Cytology: Definitions, Criteria, and Explanatory Notes (New York: Springer).
23. Sherman ME, Schiffman MH, Lorincz AT, et al (1994) Toward objective quality assurance in cervical cytopathology. Correlation of cytopathologic diagnoses with detection of high-risk human papillomavirus types Am J Clin Pathol 102 182-7 PMID: 8042586 (Pubitemid 24320521)
24. Jones BA, Novis DA (2000) Follow up of abnormal gynaecologic cytology: a college of American pathologists Q-probes study of 16132 cases from 306 laboratories Arch Pathol Lab Med 124 665-71 PMID: 10782145 (Pubitemid 30321866)
25. Wright TC Jr, Lorincz AT, Ferris DG et al (1998) Reflex HPV-DNA testing in women with abnormal Papanicolaou smears Am J Obstet Gynecol 178 962-6 DOI: 10.1016/S0002-9378(98)70531-9 PMID: 9609567
26. Schiffman M, Adrianza ME (2000) ASCUS-LSIL Triage Study. Design, methods and characteristics of trial participants Acta Cytol 44 726-42 DOI: 10.1159/000328554 PMID: 11015972
27. Solomon D, Schiffman M, Tarone R, ALTS Study Group (2001) Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial J Natl Cancer Inst 93 293-9 DOI: 10.1093/jnci/93.4.293 PMID: 11181776 (Pubitemid 32219816)
28. Kendall BS, Zhan CM (2009) The use of reflex high-risk human papillomavirus testing for atypical squamous cells of undetermined significance interpretations on vaginal specimens Cancer Cytopathol 117 27-31 DOI: 10.1002/cncy.20012
29. Dane C, Batmaz G, Dane B, Cetin A (2009) Screening properties of human papillomavirus testing for predicting cervical intraepithelial neoplasia in atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesion smears: a prospective study Ann Diagn Pathol 13 73-7 DOI: 10.1016/j.anndiagpath.2008.12.001 PMID: 19302953
30. ASCUS-LSIL Triage Study (ALTS) Group (2003) Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance Am J Obstet Gynecol 188 1383-92 PMID: 12824967
31. Costa S, De Simone P, Venturoli S et al (2003) Factors predicting human papillomavirus clearance in cervical intraepithelial neoplasia lesions treated by conization Gynecol Oncol 90358-65 DOI: 10.1016/S0090-8258(03)00268-3 PMID: 12893200
32. Costa S, De Nuzzo M, Infante FE et al (2002) Disease persistence in patients with cervical intraepithelial neoplasia undergoing electrosurgical conization Gynecol Oncol 85 119-24 DOI: 10.1006/gyno.2001.6579 PMID: 11925130 (Pubitemid 34304020)
33. Melnikow J, McGahan C, Sawaya GF, Ehlen T, Coldman A (2009) Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia cohort study J Natl Cancer Inst 101 721-8 DOI: 10.1093/jnci/djp089 PMID: 19436026 PMCID: 2684554
34. Venturoli S, Ambretti S, Cricca M et al (2008) Correlation of high-risk human papillomavirus genotypes persistence and risk of residual or recurrent cervical disease after surgical treatment J Med Virol 80 1434-40 DOI: 10.1002/jmv.21198 PMID: 18551620 (Pubitemid 351897416)
35. Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J (2005) Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence Gynecol Oncol 99 7-11 DOI: 10.1016/j.ygyno.2005.07.033
36. Sarian LO, Derchain SF, Pitta Dda R, Morais SS, Rabelo-Santos SH (2004) Factors associated with HPV persistence after treatment for high-grade cervical intra-epithelial neoplasia with large loop excision of the transformation zone (LLETZ) J Clin Virol 31 270-4 DOI: 10.1016/j.jcv.2004.05.012 PMID: 15494268 (Pubitemid 39371059)
37. Zielinski GD, Bais AG, Helmerhorst TJ et al (2004) HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis Obstet Gynecol Surv 59 543-53 DOI: 10.1097/00006254-200407000- 00024 PMID: 15199273 (Pubitemid 38802827)
38. Smith HO, Tiffany MF, Qualis CR, Key CR (2000) The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the US. A 24-year population based study Gynecol Oncol 78 97-105 DOI: 10.1006/gyno.2000.5826 PMID: 10926787 (Pubitemid 30650338)
39. Bryson P, Stulberg R, Shepherd L, McLelland K, Jeffrey J (2004) Is electrosurgical loop excision with negative margins sufficient treatment for cervical ACIS? Gynecol Oncol 93 465-8 DOI: 10.1016/j.ygyno.2004.01.028 PMID: 15099963 (Pubitemid 38507619)
40. ACOG Practice Bulletin Number 66 (September 2005) Management of abnormal cervical cytology and histology Obstet Gynecol 106 645-64 PMID: 16135610
41. Cohn DE, Morrison CD, Zanagnolo VL, Goist M, Copeland LJ (2005) Invasive cervical adenocarcinoma immediately following a cone biopsy for adenocarcinoma in situ with negative margins Gynecol Oncol 98 158-60 DOI: 10.1016/j.ygyno.2005. 04.013 PMID: 15913738 (Pubitemid 40826435)
42. Costa S, Negri G, Sideri M et al (2007) Human papillomavirus (HPV) test and PAP smear as predictors of outcome in conservatively treated adenocarcinoma in situ (AIS) of the uterine cervix Gynecol Oncol 106 170-6 DOI: 10.1016/j.ygyno.2007.03.016 PMID: 17481701 (Pubitemid 46898589)
43. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ (1992) Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types Obstet Gynecol 79 328-37 DOI: 10.1097/00006250- 199203000-00002 PMID: 1310805
44. Munoz N, Bosch FX, de Sanjose S et al (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer N Engl J Med 348 518-27 DOI: 10.1056/NEJMoa021641 PMID: 12571259 (Pubitemid 36159887)
45. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M (2007) Risk assessment to guide the prevention of cervical cancer Am J Obstet Gynecol 197 356.e1-e6 DOI: 10.1016/j.ajog.2007.07.049 PMID: 17904958
46. Castle PE, Solomon D, Schiffman M, Wheeler CM (2005) Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities J Natl Cancer Inst 97 1066-71 DOI: 10.1093/jnci/dji186 PMID: 16030304 (Pubitemid 41417923)
47. Gök M, Coupé VMH, Berkhof J et al (2007) HPV16 and increased risk of recurrence after treatment for CIN Gynecol Oncol 104 273-5 DOI: 10.1016/j.ygyno.2006.10.011 (Pubitemid 46135672)
48. Bray F, Loos AH, McCarron P et al (2005) Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening Cancer Epidemiol Biomarkers Prev 14 677-86 DOI: 10.1158/1055-9965.EPI- 04-0569 PMID: 15767349 (Pubitemid 40489214)
49. Cutts FT, Franceschi S, Goldies S et al (2007) Human papillomavirus and HPV vaccines: a review Bull World Health Organ 85 719-26 DOI: 10.2471/BLT.06.038414 PMID: 18026629 (Pubitemid 47416724)
50. Stanley M (2010) Prospects for new human papillomavirus vaccines Curr Opin Infect Dis 23 70-5 DOI: 10.1097/QCO.0b013e328334c0e1
51. Arbyn M, Anttila A, Jordan J et al (2008) European Guidelines for Quality Assurance in Cervical Cancer Screening, 2nd edn. (Luxembourg: Office for Official Publications of the European Communities, European Commission).
52. Ronco G, Segnan N, Giorgi-Rossi P et al New Technologies for Cervical Cancer Working Group (2006) Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial J Natl Cancer Inst 98 765-74 DOI: 10.1093/jnci/djj209 PMID: 16757701
53. Berkhof J, Coupé VM, Bogaards JA et al (Jan 28, 2010) The health and economic effects of HPV DNA screening in The Netherlands Int J Cancer [Epub ahead of print]
54. Mesher D, Szarewski A, Cadman L et al (2010) Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study Br J Cancer 102 1405-10 DOI: 10.1038/sj.bjc.6605619 PMID: 20354519 PMCID: 2865748
55. Kitchener HC, Almonte M, Thomson C et al (2009) HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial Lancet Oncol 10 672-82 DOI: 10.1016/S1470- 2045(09)70156-1 PMID: 19540162
56. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB (2000) Mathematical model for the natural history of Human Papillomavirus infection and cervical carcinogenesis Am J Epidemiol 151 1158-71 DOI: 10.1093/oxfordjournals.aje. a010166 PMID: 10905528 (Pubitemid 30451948)
57. Kim J, Wright TC, Goldie SJ (2005) Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy J Natl Cancer Inst 97 888-95 DOI: 10.1093/jnci/dji162 PMID: 15956650
58. Leinonen M, Nieminen P, Kotaniemi-Talonen L et al (2009) Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting J Natl Cancer Inst 101 1612-23 DOI: 10.1093/jnci/djp367 PMID: 19903804
59. Muhlberger N, Sroczynski G, Esteban E, Mittendorf T, Miksad RA, Siebert U (2008) Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: a systematic review commissioned by the German Federal Ministry of Health Int J Technol Assess Health Care 24 184-92 DOI: 10.1017/S0266462308080264 PMID: 18400122 (Pubitemid 351519518)
60. Goldhaber-Fiebert D, Stout NK, Salomon JA, Kuntz KM, Goldie SJ (2008) Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination J Natl Cancer Inst 100 308-20 DOI: 10.1093/jnci/djn019 PMID: 18314477 (Pubitemid 351480523)
61. Kulasingam SL, Kim JJ, Lawrence WF et al ALTS Group (2006) Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS) J Natl Cancer Inst 98 92-100 DOI: 10.1093/jnci/djj009 PMID: 16418511 (Pubitemid 43159963)
62. Anhang R, Goodman A, Goldie SJ (2004) HPV communication: review of existing research and recommendations for patient education CA Cancer J Clin 54 248-59 DOI: 10.3322/canjclin.54.5.248 PMID: 15371283 (Pubitemid 39419765)
63. Bertram CC, Magnussen L (2008) Informational needs and the experiences of women with abnormal Papanicolaou smears J Am Acad Nurse Pract 20 455-62 DOI: 10.1111/j.1745-7599.2008.00341.x PMID: 18786022
64. Sussman AL, Helitzer D, Sanders M, Urquieta B, Salvador M, Ndiaye K (2007) HPV and cervical cancer prevention counseling with younger adolescents: implications for primary care Ann Fam Med 5 298-304 DOI: 10.1370/afm.723 PMID: 17664495 (Pubitemid 47294845)
65. Castle PE, Rodriguez AC, Burk RD et al (2009) Neither one-time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer Int J Cancer 125 1649-56 DOI: 10.1002/ijc.24525 PMID: 19569231 PMCID: 2766540